North America (NASoP)
The creation of ISoPâs North American chapter (NASoP) was officially announced on 3rd October 2013 at the Annual ISoP Meeting in Pisa, Italy (AGM).
Committee
Tina Bostic
(PPD)Abimbola Cole
(Takeda)Dinesh Kasthuril
(Covance)Marina Malikova
(Boston University)ISoP Chapters
ISoP North America (NASoP) Chapter
Chapter Webinar
14 September 2023 | 08.00 EDT (12.00 UTC)
Free webinar for ISoP members, organized by the North America Chapter (NASoP) of ISoP and presented by:
Dr. Tarek Hammad,
VP & Head of Medical Safety for Marketed Products at Takeda Pharmaceuticals
Dr. Salman Afsar,
Senior Director and Signal Management Team Chair at Bristol Myers Squibb.
Click image to view
All webinars are recorded and are available for ISoP members.
This chapter includes members from Canada and USA.
All ISoP members, who currently live in other countries, but have professional ties with the North American countries are welcome to join this Chapter (including and not restrictive to Mexico, Bahamas, etcâŠ).
The chapter will provide a platform for promoting Pharmacovigilance to a broader audience, educating and communicating on all its current and future aspects and its vital impact in the Drug development process and Health care system.
It aims at being inclusive of the many already existing associations and businesses whose common goal is a better understanding of what PV is, fostering the relationships with existing PV stakeholders and new one, such as patients group and therefore strengthen this specialty on the North American continent and develop the PV specialists of the next generations working on the PV issues of tomorrow.
By means of meetings, workshops, bulletins, trainings and specifically organising NASoP congresses, and using existing professional social media supports and creating NASoP App.
Chapter Objectives
- Encouraging and extending research in the field of 21st century Pharmacovigilance, embedding Pharmacogenomics, Pharmacoepidemiology tools
- Promoting a regular exchange of information on Pharmacovigilance by means of meetings, symposia, workshops, bulletins, trainings and specifically organising NASoP congresses
- Creating a NASoP App for easier, broader communication with all Stakeholders of Pharmacovigilance
- Encouraging Pharmacovigilance education at all levels
- Embedding Pharmacovigilance in Health Care Professionals academic trainings
- Cooperating with other organizations and societies concerned with Pharmacovigilance: WHO, UMC, ISoP
- Publishing scientific and other relevant aspects relating to Pharmacovigilance
- Providing a platform for debate and communication among the principal stakeholders of adverse drug reactions, including patientsâs organization
NASoP Annual Meeting 2022
Delivered virtually as a Zoom Webinar on November 07 & 08, 2022 (08.00 to 12.10 EST)
This yearâs NASoP Annual meeting will focus on pharmacovigilance in three key diverse areas: Cancer, the COVID-19 Pandemic and the Opioid Epidemic. Challenges, lessons learned as well as opportunities will be discussed by leaders within the pharmaceutical industry, academia and health economics.
Join NASoP for this 2-day event to learn from and engage with several healthcare and pharmacovigilance professionals. The meeting is virtual and registration is free!
We hope you will join ISoP to collaborate with other pharmacovigilance experts. To join ISoP and enjoy reduced membership fees, please visit our âHow to Joinâ page.
NASoP-DIA joint webinar series 2022
February 3rd, March 3rd, April 7th, and May 5th, 2022 (11.00 EST)
DIA and NASoP have collaborated to offer a series of four, one-hour, monthly webinars on the topic of Drug Interactions, led by renowned experts, in February to May 2022. Registration is free.
We hope you will join ISoP to collaborate with other pharmacovigilance experts. To join ISoP and enjoy reduced membership fees, please visit our âHow to Joinâ page.
NASoP COVID-19 Working Group
NASoP has recently launched a COVID-19 Working Group to address multiple aspects of the COVID-19 pandemic from the perspective of the Pharmacovigilance practice.
Topics currently being explored include:
- The role of Pharmacovigilance in accelerated drug approvals for COVID-19 treatments
- The impact of COVID19 in AE reporting and assessment from ongoing clinical trials and post-marketing data
- Safety considerations in Off-label drug use for COVID-19
- Exploration of vaccines and drugs in development
- Health Authority interactions regarding COVID-19 treatment
- The role of collaboration and data sharing across the healthcare industry
If you are a current member of ISoP and would like to join the NASoP COVID-19 working group or are part of another ISoP chapter and would like to collaborate, please reach out to Veronique Kugener, NASoP Chair or Kenneth Maynard, NASoP Secretariat.
Visit the new section of the website dedicated to information on pharmacovigilance of medicinal products used to treat and prevent COVID-19 (coronavirus). Click here.
NASoP Annual Meeting 2018
November 2nd, 2018 â Roundtable: Structured Benefit-Risk Assessment Across the Therapeutic Product Lifecycle.
Takeda Boston â For more information, please click here
Most of the presentations of the NASoP Annual Meeting 2018 are now available on the Members Section of the website. Click here to access to the presentations (for ISoP members only).
Would you like to join or learn more about this chapter? Contact us at administration@isoponline.org
